According to the design of the study and Italian law, in which only well-established routine tests for the management of T2D and/or CVD were allowed, we could not plan some evaluations, such as C peptide, insulin endogenous plasma IL-1Ra, as well as laboratory markers of endothelial dysfunction, which would be of interest [10,16,34–36]. The gene discussed is INS; the disease is type 2 diabetes mellitus.